BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 17073663)

  • 1. 5-HT3 receptors.
    Thompson AJ; Lummis SC
    Curr Pharm Des; 2006; 12(28):3615-30. PubMed ID: 17073663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 5-HT3 receptor as a therapeutic target.
    Thompson AJ; Lummis SC
    Expert Opin Ther Targets; 2007 Apr; 11(4):527-40. PubMed ID: 17373882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-HT(3) receptors.
    Lummis SC
    J Biol Chem; 2012 Nov; 287(48):40239-45. PubMed ID: 23038271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformational Changes in the 5-HT
    Munro L; Ladefoged LK; Padmanathan V; Andersen S; Schiøtt B; Kristensen AS
    Mol Pharmacol; 2019 Dec; 96(6):720-734. PubMed ID: 31582575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational analysis of ligand recognition sites of homo- and heteropentameric 5-HT3 receptors.
    Moura Barbosa AJ; De Rienzo F; Ramos MJ; Menziani MC
    Eur J Med Chem; 2010 Nov; 45(11):4746-60. PubMed ID: 20724042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of recognition loops B and D in the activation of human 5-HT₃ receptors by 5-HT and meta-chlorophenylbiguanide.
    Michaelson SD; Paulsen IM; Kozuska JL; Martin IL; Dunn SM
    Neuropharmacology; 2013 Oct; 73():398-403. PubMed ID: 23810831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a novel allosteric modulator of 5-HT3 receptors: inhibition and potentiation of Cys-loop receptor signaling through a conserved transmembrane intersubunit site.
    Trattnig SM; Harpsøe K; Thygesen SB; Rahr LM; Ahring PK; Balle T; Jensen AA
    J Biol Chem; 2012 Jul; 287(30):25241-54. PubMed ID: 22589534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity amongst 5-HT₃ receptor subunits: is this significant?
    Yaakob N; Malone DT; Exintaris B; Irving HR
    Curr Mol Med; 2011 Feb; 11(1):57-68. PubMed ID: 21189117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visualising functional 5-HT
    Abad IPL; Fam RL; Nguyen DT; Nowell CJ; Trinh PNH; Manallack DT; Freihat LA; Chakrabarti J; Jamil A; Exintaris B; Yaakob NS; Irving HR
    Biomed Pharmacother; 2020 Dec; 132():110860. PubMed ID: 33059258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutics of 5-HT3 receptor antagonists: current uses and future directions.
    Machu TK
    Pharmacol Ther; 2011 Jun; 130(3):338-47. PubMed ID: 21356241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and electrophysiological properties of the naturally occurring Pro391Arg variant of the human 5-HT3A receptor.
    Kurzwelly D; Barann M; Kostanian A; Combrink S; Bönisch H; Göthert M; Brüss M
    Pharmacogenetics; 2004 Mar; 14(3):165-72. PubMed ID: 15167704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the novel human serotonin receptor subunits 5-HT3C,5-HT3D, and 5-HT3E.
    Niesler B; Walstab J; Combrink S; Möller D; Kapeller J; Rietdorf J; Bönisch H; Göthert M; Rappold G; Brüss M
    Mol Pharmacol; 2007 Jul; 72(1):8-17. PubMed ID: 17392525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of 5-HT3C, 5-HT3D and 5-HT3E receptor subunits: evolution, distribution and function.
    Holbrook JD; Gill CH; Zebda N; Spencer JP; Leyland R; Rance KH; Trinh H; Balmer G; Kelly FM; Yusaf SP; Courtenay N; Luck J; Rhodes A; Modha S; Moore SE; Sanger GJ; Gunthorpe MJ
    J Neurochem; 2009 Jan; 108(2):384-96. PubMed ID: 19012743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agonists and antagonists bind to an A-A interface in the heteromeric 5-HT3AB receptor.
    Lochner M; Lummis SC
    Biophys J; 2010 Apr; 98(8):1494-502. PubMed ID: 20409468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments in 5-HT3 receptor pharmacology.
    Thompson AJ
    Trends Pharmacol Sci; 2013 Feb; 34(2):100-9. PubMed ID: 23380247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subunit-dependent inhibition and potentiation of 5-HT3 receptor by the anticancer drug, topotecan.
    Nakamura Y; Ishida Y; Yamada T; Kondo M; Shimada S
    J Neurochem; 2013 Apr; 125(1):7-15. PubMed ID: 23305320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allosteric activation of the 5-HT3AB receptor by mCPBG.
    Miles TF; Lester HA; Dougherty DA
    Neuropharmacology; 2015 Apr; 91():103-8. PubMed ID: 25541413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unbinding pathways of an agonist and an antagonist from the 5-HT3 receptor.
    Thompson AJ; Chau PL; Chan SL; Lummis SC
    Biophys J; 2006 Mar; 90(6):1979-91. PubMed ID: 16387779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric modulation of the 5-HT(3) receptor.
    Davies PA
    Curr Opin Pharmacol; 2011 Feb; 11(1):75-80. PubMed ID: 21342788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Chloroindole: a potent allosteric modulator of the 5-HT₃ receptor.
    Newman AS; Batis N; Grafton G; Caputo F; Brady CA; Lambert JJ; Peters JA; Gordon J; Brain KL; Powell AD; Barnes NM
    Br J Pharmacol; 2013 Jul; 169(6):1228-38. PubMed ID: 23594147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.